NOVEL THERAPIES FOR INFLAMMATORY DISEASES THAT DEPEND ON
NLRP3 INFLAMMASOME ACTIVITY
OUR SCIENCE
Apaxen is developing innovative treatments for patients with diseases that depend on chronic NLRP3 Inflammasome activation and high expression of MIF (Macrophage Migration Inhibitory factor).
This platform allows for the development of novel treatments for many inflammatory, auto-immune and inflammaging related diseases, as well as many cancers.
PIPELINE
Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 Inflammasome activation and MIF. Pulmonary arterial hypertension (PAH) is the primarily targeted indication.
LATEST NEWS & PUBLICATIONS
Belgian biotech Apaxen appoints Bart Wuurman as CEO
Gosselies, Belgium, November 12, 2020 – Apaxen S.A., a privately-held preclinical stage biotechnology company, developing novel oral drugs for chronic inflammatory diseases, with a primary…
PR – Apaxen raises €3.3 million in Series A Financing
Apaxen raises €3.3 million in Series A Financing to Develop Breakthrough Anti-inflammatory Therapeutics for Pulmonary Arterial Hypertension.
